5:34 PM
 | 
Apr 10, 2013
 |  BC Extra  |  Clinical News

GSK reports mixed Phase IIb data for drisapersen for DMD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said continuous dosing with once-weekly subcutaneous drisapersen met the primary endpoint of improving six-minute walk distance (6MWD) from baseline to week 24 vs. placebo in the Phase IIb DMD114117 trial to treat Duchenne muscular dystrophy (DMD). However, intermittent dosing of drisapersen for six weeks of a 10-week cycle...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >